Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Shandong Weigao Group Medical Polymer Co stock

1066.HK
CNE100000171
A0M4WA

Price

4.36
Today +/-
-0.04
Today %
-7.45 %
P

Shandong Weigao Group Medical Polymer Co stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Shandong Weigao Group Medical Polymer Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Shandong Weigao Group Medical Polymer Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Shandong Weigao Group Medical Polymer Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Shandong Weigao Group Medical Polymer Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Shandong Weigao Group Medical Polymer Co Stock Price History

DateShandong Weigao Group Medical Polymer Co Price
11/5/20244.36 undefined
11/5/20244.70 undefined
11/4/20244.51 undefined
11/1/20244.45 undefined
10/31/20244.44 undefined
10/30/20244.45 undefined
10/29/20244.58 undefined
10/28/20244.65 undefined
10/25/20244.53 undefined
10/24/20244.49 undefined
10/23/20244.54 undefined
10/22/20244.65 undefined
10/21/20244.57 undefined
10/18/20244.50 undefined
10/17/20244.43 undefined
10/16/20244.52 undefined
10/15/20244.60 undefined
10/14/20244.82 undefined
10/10/20245.02 undefined
10/9/20245.03 undefined
10/8/20245.38 undefined

Shandong Weigao Group Medical Polymer Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Shandong Weigao Group Medical Polymer Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Shandong Weigao Group Medical Polymer Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Shandong Weigao Group Medical Polymer Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Shandong Weigao Group Medical Polymer Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Shandong Weigao Group Medical Polymer Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Shandong Weigao Group Medical Polymer Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Shandong Weigao Group Medical Polymer Co’s growth potential.

Shandong Weigao Group Medical Polymer Co Revenue, EBIT and net profit per share

DateShandong Weigao Group Medical Polymer Co RevenueShandong Weigao Group Medical Polymer Co EBITShandong Weigao Group Medical Polymer Co Net Income
2026e15.92 B undefined3.03 B undefined2.55 B undefined
2025e15.02 B undefined2.84 B undefined2.36 B undefined
2024e14.07 B undefined2.64 B undefined2.18 B undefined
202313.23 B undefined2.35 B undefined2 B undefined
202213.75 B undefined3.19 B undefined2.76 B undefined
202113.21 B undefined3.1 B undefined2.28 B undefined
202011.62 B undefined2.74 B undefined2.09 B undefined
201910.38 B undefined2.44 B undefined1.85 B undefined
20188.81 B undefined1.84 B undefined1.47 B undefined
20176.29 B undefined1.47 B undefined1.73 B undefined
20165.62 B undefined1.17 B undefined1.11 B undefined
20155.92 B undefined1.32 B undefined1.11 B undefined
20145.28 B undefined1.16 B undefined1.08 B undefined
20134.61 B undefined1.09 B undefined388 M undefined
20123.69 B undefined912.2 M undefined996.5 M undefined
20113.18 B undefined899.4 M undefined3.59 B undefined
20102.46 B undefined691.7 M undefined799.1 M undefined
20091.88 B undefined563.8 M undefined633.9 M undefined
20081.51 B undefined489.9 M undefined482.4 M undefined
20071.1 B undefined291 M undefined308.1 M undefined
2006786.9 M undefined178.4 M undefined170.9 M undefined
2005570 M undefined121.6 M undefined101.2 M undefined
2004407.8 M undefined81.7 M undefined65.9 M undefined

Shandong Weigao Group Medical Polymer Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (B)DOCUMENTS
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
0.210.280.320.410.570.791.11.511.882.463.183.694.615.285.925.626.298.8110.3811.6213.2113.7513.2314.0715.0215.92
-32.3814.0328.3940.0537.8939.3138.2624.0431.1029.1616.0125.0514.3912.15-5.0511.9839.9917.8811.9313.654.08-3.776.356.726.03
30.0038.1341.6440.0541.0542.6245.6650.0753.3055.2055.3557.2559.0958.8259.4063.6663.4561.1862.7355.9255.6153.0449.97---
0.060.110.130.160.230.340.50.7611.361.762.112.733.13.523.583.995.396.516.57.357.296.61000
0.010.050.070.080.120.180.290.490.560.690.90.911.091.161.321.171.471.842.442.743.13.192.352.642.843.03
6.1919.0621.4519.9021.2322.6526.5832.3029.9828.0728.2724.7223.6521.9322.3220.8623.4320.8723.5423.6023.4823.1817.7718.7418.9019.04
0.010.040.050.070.10.170.310.480.630.83.5910.391.081.111.111.731.471.852.092.282.7622.182.362.55
-330.0016.2830.0055.3868.3281.1856.4931.3326.22348.81-72.23-61.04179.382.58-0.6356.38-14.8125.6112.829.0621.49-27.608.708.377.98
--------------------------
--------------------------
2.42.42.43.293.63.863.953.994.314.314.424.484.484.484.484.484.484.484.484.494.524.534.52000
--------------------------
Details

Keystats

Revenue and Growth

The Shandong Weigao Group Medical Polymer Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Shandong Weigao Group Medical Polymer Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (B)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (M)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                             
00.020.030.110.170.120.260.830.720.631.851.33.022.793.714.073.784.164.676.147.136.966.99
0.060.080.10.140.190.280.390.560.720.871.131.291.752.142.452.932.853.463.894.645.035.495.69
000000.050.050.090.090.120.220.250.370.660.390.631.381.582.231.341.112.162.03
0.050.040.060.070.120.170.250.290.320.380.460.830.870.910.850.920.811.141.251.561.782.322.5
0.020.020.030.040.070.050.130.120.140.20.210.210.250.30.150.140.230.380.580.71.21.341.43
0.120.160.210.360.550.661.081.8922.23.873.876.256.87.568.689.0510.7212.6114.3716.2618.2918.63
0.130.180.30.360.520.640.820.921.171.412.043.264.034.295.015.413.984.615.566.16.737.327.34
00.010.010.010.010.040.090.160.320.582.412.640.250.270.190.261.211.211.631.51.561.992.03
00000000000.010000.030.631.831.230.780.30.360.210.16
00000.060.050.120.160.260.250.020.020.020.010.010.050.042.412.272.061.81.721.51
0000000.030.20.20.20.20.20.20.20.20.20.23.343.43.413.353.643.73
000000781013819486538499.56521.14525.6465.66464.96101.02228.23529.64231.78270.07
0.130.190.310.380.580.741.061.451.962.455.56.615.045.275.967.077.7313.2713.7413.5914.3215.1115.04
0.250.340.520.741.131.392.143.343.954.659.3710.4811.2912.0713.5215.7616.7823.9926.3527.9630.5833.433.67
                                             
606060869797100108108215448448448447.64447.64452.23452.23452.23452.23452.23457.06457.06457.06
0000.130.230.230.621.391.391.292.4802.482.482.482.582.572.582.582.582.742.742.74
0.010.050.10.160.240.370.610.981.442.135.298.466.126.927.738.810.2511.2912.9215.116.3718.419.03
0000000-1-10-170-2-1.795.7738.3756.01194.7236.48-93.27-163.07166.76216.11
00000000000000000000000
0.070.110.160.370.570.71.332.482.943.638.28.919.049.8510.6611.8713.3314.5116.1818.0319.4121.7722.45
0.050.070.10.090.170.180.280.410.480.590.761.010.990.670.480.590.650.951.141.761.631.714.32
000000000000000101.3109.4865.57103.81134.91119.92206.030
0.040.040.030.020.030.080.140.270.350.290.310.520.791.061.151.591.342.072.282.42.813.10.69
000000000000000104.41103.31114.23143.980000
0.010.020.080.110.130.110.1300.040.030.0200.30.270.370.30.10.130.920.310.620.992.57
0.090.120.210.210.320.370.550.680.870.911.081.532.08222.682.33.334.584.65.186.017.58
0.090.110.160.150.210.280.210.140.110.090.0600.10.150.650.790.85.094.454.013.513.51.6
00000000000000000339.57278.42291.8222.62199.8165.79
000000039302016294338.4981.5975.3234.8336.7945.85174.66617.3113.74333.71
0.090.110.160.150.210.280.210.180.140.110.080.030.140.190.730.870.845.474.784.484.353.812.1
0.180.230.360.360.530.650.760.861.011.011.161.562.232.192.733.553.148.89.369.089.539.829.68
0.250.340.520.731.11.352.093.333.954.649.3610.4711.2712.0413.3915.4216.4823.3125.5427.1128.9431.5932.13
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Shandong Weigao Group Medical Polymer Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Shandong Weigao Group Medical Polymer Co's financial health and stability.

Assets

Shandong Weigao Group Medical Polymer Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Shandong Weigao Group Medical Polymer Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Shandong Weigao Group Medical Polymer Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Shandong Weigao Group Medical Polymer Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
0.010.050.060.070.10.190.330.520.710.893.591.130.541.281.341.312.081.782.252.572.883.32
58111623434860749497128187243314350365559607702731798
0000000000000000000000
-13-14-21-82-32-51-78-111-152-259-400-221-581-694-665-980-883-277-813-639-675-1,654
45131424-4-25-35-148-199-2,669-226569-11368368-300162275159152-247
1211111721213548341628475659271333181127184
028110101349102134116177170199137295240473388481483
0.010.050.060.020.120.180.280.440.480.520.620.810.720.711.051.051.272.222.322.793.092.21
-69-52-133-81-165-110-252-207-407-350-1,325-1,023-1,014-750-1,130-621-1,512-795-985-1,007-1,166-1,116
-56-63-138-91-158-157-385-294-424-401-449-1,015875-619-418-876-1,808-6,087-1,337383-1,517-2,568
0.01-0.01-0-0.010.01-0.05-0.13-0.09-0.02-0.050.880.011.890.130.71-0.26-0.3-5.29-0.351.39-0.35-1.45
0000000000000000000000
0.050.030.110.020.06-0-0.05-0.20.01-0.04-0.03-0.080.40.020.60.170.244.070.01-1.06-0.220.06
0000.170.0700.390.78001.43000000-0.01-0.020.050.1-0.04
0.050.030.090.160.1-0.060.250.43-0.16-0.221.08-0.370.12-0.290.290.180.263.87-0.57-1.79-0.55-1.02
-1-2-11-25-16-19-21-35-4-68-25-4-2-282125451133162-84228-304
00-9-6-20-38-69-115-171-113-297-282-277-277-331-252-490-217-711-701-653-741
00.010.010.080.06-0.040.140.57-0.11-0.091.22-0.551.68-0.190.930.36-0.290.030.431.320.97-1.28
-61.3-2.2-73.8-63.6-47.266.123.4230.271.4173.4-704.3-217.9-294.1-39.44-77.88432.04-246.791,423.721,337.11,781.061,920.411,098.34
0000000000000000000000

Shandong Weigao Group Medical Polymer Co stock margins

The Shandong Weigao Group Medical Polymer Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Shandong Weigao Group Medical Polymer Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Shandong Weigao Group Medical Polymer Co.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Shandong Weigao Group Medical Polymer Co's sales revenue. A higher gross margin percentage indicates that the Shandong Weigao Group Medical Polymer Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Shandong Weigao Group Medical Polymer Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Shandong Weigao Group Medical Polymer Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Shandong Weigao Group Medical Polymer Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Shandong Weigao Group Medical Polymer Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Shandong Weigao Group Medical Polymer Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Shandong Weigao Group Medical Polymer Co Margin History

Shandong Weigao Group Medical Polymer Co Gross marginShandong Weigao Group Medical Polymer Co Profit marginShandong Weigao Group Medical Polymer Co EBIT marginShandong Weigao Group Medical Polymer Co Profit margin
2026e49.97 %19.04 %15.99 %
2025e49.97 %18.9 %15.7 %
2024e49.97 %18.74 %15.46 %
202349.97 %17.77 %15.13 %
202253.05 %23.18 %20.11 %
202155.61 %23.48 %17.23 %
202055.92 %23.6 %17.95 %
201962.73 %23.54 %17.82 %
201861.18 %20.87 %16.72 %
201763.45 %23.43 %27.47 %
201663.66 %20.86 %19.68 %
201559.4 %22.32 %18.8 %
201458.82 %21.93 %20.56 %
201359.11 %23.66 %8.41 %
201257.26 %24.73 %27.01 %
201155.34 %28.28 %112.76 %
201055.21 %28.09 %32.45 %
200953.3 %30.01 %33.75 %
200850.07 %32.35 %31.85 %
200745.69 %26.57 %28.13 %
200642.61 %22.67 %21.72 %
200541.11 %21.33 %17.75 %
200439.97 %20.03 %16.16 %

Shandong Weigao Group Medical Polymer Co Stock Sales Revenue, EBIT, Earnings per Share

The Shandong Weigao Group Medical Polymer Co earnings per share therefore indicates how much revenue Shandong Weigao Group Medical Polymer Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Shandong Weigao Group Medical Polymer Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Shandong Weigao Group Medical Polymer Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Shandong Weigao Group Medical Polymer Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Shandong Weigao Group Medical Polymer Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Shandong Weigao Group Medical Polymer Co Revenue, EBIT and net profit per share

DateShandong Weigao Group Medical Polymer Co Sales per ShareShandong Weigao Group Medical Polymer Co EBIT per shareShandong Weigao Group Medical Polymer Co Earnings per Share
2026e3.52 undefined0 undefined0.56 undefined
2025e3.32 undefined0 undefined0.52 undefined
2024e3.11 undefined0 undefined0.48 undefined
20232.93 undefined0.52 undefined0.44 undefined
20223.04 undefined0.7 undefined0.61 undefined
20212.92 undefined0.69 undefined0.5 undefined
20202.59 undefined0.61 undefined0.46 undefined
20192.32 undefined0.55 undefined0.41 undefined
20181.96 undefined0.41 undefined0.33 undefined
20171.4 undefined0.33 undefined0.39 undefined
20161.26 undefined0.26 undefined0.25 undefined
20151.32 undefined0.3 undefined0.25 undefined
20141.18 undefined0.26 undefined0.24 undefined
20131.03 undefined0.24 undefined0.09 undefined
20120.82 undefined0.2 undefined0.22 undefined
20110.72 undefined0.2 undefined0.81 undefined
20100.57 undefined0.16 undefined0.19 undefined
20090.44 undefined0.13 undefined0.15 undefined
20080.38 undefined0.12 undefined0.12 undefined
20070.28 undefined0.07 undefined0.08 undefined
20060.2 undefined0.05 undefined0.04 undefined
20050.16 undefined0.03 undefined0.03 undefined
20040.12 undefined0.02 undefined0.02 undefined

Shandong Weigao Group Medical Polymer Co business model

Shandong Weigao Group Medical Polymer Co Ltd is a globally operating company with headquarters in Weihai, China. It was founded in 1988 and has been listed on the Hong Kong Stock Exchange since 2004. The company specializes in the production of medical polymer products and offers a wide range of products for various applications. Its business model is that of an integrated platform for research, development, manufacturing, and marketing of medical devices. Their customers include hospitals, medical practices, and distributors worldwide. The company's portfolio includes products in the areas of infusion, blood transfusion, dialysis, surgery, anesthesia, first aid, and diagnostics. Both disposable and reusable products are available. With its offering, the company aims to contribute to improving the quality of healthcare and providing better outcomes for patients. Shandong Weigao Group Medical Polymer Co Ltd is divided into three divisions: Medical Devices, Medical Consumables, and Biology. The Medical Devices division manufactures devices for use in anesthesia, surgery, resuscitation, and diagnostics. The Medical Consumables division includes products such as syringes, catheters, infusion and transfusion devices, disposable gloves, and wound dressings. The Biology division specializes in the development, manufacturing, and marketing of biopharmaceutical products, such as insulin. The company's history is characterized by rapid expansion and continuous growth. The focus on R&D has played an important role in this. Through the use of advanced technologies, the company has acquired a multitude of patents in both China and other countries. The company places a strong emphasis on quality assurance and has implemented a comprehensive quality control system. In addition, it aims to minimize its environmental impact and therefore operates according to the latest environmental standards. In recent years, the company has established an international presence and opened subsidiaries in Europe and the USA. This demonstrates the company's desire to grow internationally and offer its products in more and more countries. In summary, Shandong Weigao Group Medical Polymer Co Ltd is an innovative company specializing in the production of medical polymer products and biopharmaceutical products. It offers a wide range of products and is committed to a comprehensive quality control system and sustainability. With its international presence, the company aims to continue growing and offer its products worldwide. Shandong Weigao Group Medical Polymer Co is one of the most popular companies on Eulerpool.com.

Shandong Weigao Group Medical Polymer Co SWOT Analysis

Strengths

Shandong Weigao Group Medical Polymer Co Ltd has several strengths that contribute to its success in the market:

  • Strong brand reputation and recognition in the medical polymer industry
  • Wide range of high-quality medical polymer products
  • Advanced production facilities and technologies
  • Established distribution network both domestically and internationally
  • Experienced and skilled workforce
  • Strong financial position and profitability
  • Continuous innovation and new product development

Weaknesses

Despite its strengths, Shandong Weigao Group Medical Polymer Co Ltd also faces certain weaknesses:

  • Dependence on a limited number of key suppliers
  • Vulnerable to fluctuations in raw material prices
  • Reliance on a few major customers for significant revenue
  • Limited diversification of product portfolio
  • Relatively limited market presence compared to some competitors
  • Challenges in maintaining competitive pricing

Opportunities

Shandong Weigao Group Medical Polymer Co Ltd can capitalize on the following opportunities:

  • Increasing demand for medical polymer products globally
  • Expanding into emerging markets with high growth potential
  • Strategic partnerships and collaborations to enhance market reach
  • Investment in research and development to drive innovation
  • Diversification into related healthcare sectors
  • Growing adoption of disposable medical products

Threats

The following threats pose challenges to Shandong Weigao Group Medical Polymer Co Ltd:

  • Intense competition from established and emerging market players
  • Regulatory changes and compliance requirements
  • Potential disruptions in the global supply chain
  • Economic downturns impacting customer purchasing power
  • Technological advancements and potential obsolescence of current products
  • Potential backlash from environmental and sustainability concerns

Shandong Weigao Group Medical Polymer Co Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Shandong Weigao Group Medical Polymer Co historical P/E ratio, EBIT multiple, and P/S ratio

Shandong Weigao Group Medical Polymer Co shares outstanding

The number of shares was Shandong Weigao Group Medical Polymer Co in 2023 — This indicates how many shares 4.519 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Shandong Weigao Group Medical Polymer Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Shandong Weigao Group Medical Polymer Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Shandong Weigao Group Medical Polymer Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Shandong Weigao Group Medical Polymer Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Shandong Weigao Group Medical Polymer Co stock splits

In Shandong Weigao Group Medical Polymer Co's history, there have been no stock splits.

Shandong Weigao Group Medical Polymer Co dividend history and estimates

In 2023, Shandong Weigao Group Medical Polymer Co paid a dividend amounting to 0.25 CNY. Dividend means that Shandong Weigao Group Medical Polymer Co distributes a portion of its profits to its owners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

Dividend Overview

The dividend per year chart for Shandong Weigao Group Medical Polymer Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Shandong Weigao Group Medical Polymer Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Shandong Weigao Group Medical Polymer Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Shandong Weigao Group Medical Polymer Co Dividend History

DateShandong Weigao Group Medical Polymer Co Dividend
2026e0.27 undefined
2025e0.27 undefined
2024e0.27 undefined
20230.25 undefined
20220.17 undefined
20210.18 undefined
20200.14 undefined
20190.13 undefined
20180.11 undefined
20170.1 undefined
20160.09 undefined
20150.09 undefined
20140.06 undefined
20130.06 undefined
20120.06 undefined
20110.07 undefined
20100.03 undefined
20090.04 undefined
20080.03 undefined
20070.02 undefined
20060.01 undefined
20050.01 undefined
20040 undefined

Shandong Weigao Group Medical Polymer Co dividend payout ratio

In 2023, Shandong Weigao Group Medical Polymer Co had a payout ratio of 30.92%. The payout ratio indicates the percentage of the company's profits that Shandong Weigao Group Medical Polymer Co distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for Shandong Weigao Group Medical Polymer Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Shandong Weigao Group Medical Polymer Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Shandong Weigao Group Medical Polymer Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Shandong Weigao Group Medical Polymer Co Payout Ratio History

DateShandong Weigao Group Medical Polymer Co Payout ratio
2026e30.78 %
2025e30.13 %
2024e31.28 %
202330.92 %
202228.18 %
202134.74 %
202029.85 %
201930.29 %
201833.79 %
201727.29 %
201637.42 %
201536.9 %
201425.58 %
201368.89 %
201228.64 %
20118.21 %
201013.82 %
200926.5 %
200824.17 %
200720.94 %
200625 %
200519.17 %
20048.75 %

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Shandong Weigao Group Medical Polymer Co.

Shandong Weigao Group Medical Polymer Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/20130.06 0.03  (-54.25 %)2013 Q4
9/30/20130.06 0.08  (27.45 %)2013 Q3
6/30/20130.07 0.05  (-36.97 %)2013 Q2
3/31/20130.05 0.05  (0 %)2013 Q1
12/31/20120.07 0.05  (-26.09 %)2012 Q4
9/30/20120.07 0.06  (-14.57 %)2012 Q3
6/30/20120.06 0.06  (0.64 %)2012 Q2
3/31/20120.05 0.05  (-5.88 %)2012 Q1
12/31/20110.07 0.16  (139.23 %)2011 Q4
9/30/20110.06 0.06  (-8.5 %)2011 Q3
1
2
3

Eulerpool ESG Scorecard© for the Shandong Weigao Group Medical Polymer Co stock

Eulerpool World ESG Rating (EESG©)

72/ 100

🌱 Environment

91

👫 Social

47

🏛️ Governance

78

Environment

Scope 1 - Direct Emissions
2,978.68
Scope 2 - Indirect emissions from purchased energy
101,426
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
104,405
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees43.73
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Shandong Weigao Group Medical Polymer Co shareholders

%
Name
Stocks
Change
Date
46.43084 % Weigao Holding Co Ltd2,099,755,676012/31/2023
3.18761 % Norges Bank Investment Management (NBIM)144,154,11052,187,5826/30/2024
2.62691 % Wellington Management Company, LLP118,797,617747,5708/31/2024
1.85158 % FIL Investment Management (Hong Kong) Limited83,734,353-48/31/2024
1.70199 % The Vanguard Group, Inc.76,969,607265,2009/30/2024
0.91992 % Dimensional Fund Advisors, L.P.41,601,60049,6009/30/2024
0.87901 % Bosera Asset Management Co., Ltd.39,751,600-423,2006/30/2024
0.87357 % BlackRock Institutional Trust Company, N.A.39,505,916162,0009/30/2024
0.81633 % British Columbia Investment Management Corp.36,917,19614,876,5983/31/2023
0.72773 % Schroder Investment Management (Hong Kong) Ltd.32,910,40006/30/2024
1
2
3
4
5
...
10

Shandong Weigao Group Medical Polymer Co Executives and Management Board

Mr. Jing Long(49)
Shandong Weigao Group Medical Polymer Co Executive Chairman of the Board (since 2016)
Compensation 12.09 M
Mr. Rinan Cong(42)
Shandong Weigao Group Medical Polymer Co Chief Executive Officer, Executive Director (since 2021)
Compensation 4.96 M
Mr. Junqiang Lu(48)
Shandong Weigao Group Medical Polymer Co Executive Director, Director and General Manager - Shandong Weigao Orthopaedic Device Company Limited (since 2021)
Compensation 1.56 M
Mr. Guohui Li(51)
Shandong Weigao Group Medical Polymer Co Non-Executive Independent Director
Compensation 97,000
Mrs. Hong Meng(57)
Shandong Weigao Group Medical Polymer Co Non-Executive Independent Director
Compensation 30,000
1
2

Most common questions regarding Shandong Weigao Group Medical Polymer Co

What values and corporate philosophy does Shandong Weigao Group Medical Polymer Co represent?

Shandong Weigao Group Medical Polymer Co Ltd represents the values of innovation, quality, and sustainability. With a strong corporate philosophy centered around patient care and healthcare advancements, the company aims to provide reliable and high-quality medical polymer products. By fostering a culture of continuous improvement and investment in research and development, Shandong Weigao Group strives to deliver innovative solutions that cater to the evolving needs of the healthcare industry. It is committed to maintaining ethical business practices and adhering to stringent quality standards, ensuring customer satisfaction and building long-term partnerships.

In which countries and regions is Shandong Weigao Group Medical Polymer Co primarily present?

Shandong Weigao Group Medical Polymer Co Ltd primarily operates in China and has established a strong presence in various regions within the country. As a leading medical polymer company, Shandong Weigao serves healthcare institutions, medical device manufacturers, and other clients across different provinces and cities within China. With its commitment to providing high-quality medical products, the company's presence can be felt throughout China, supporting the healthcare industry's needs and contributing to improving medical care.

What significant milestones has the company Shandong Weigao Group Medical Polymer Co achieved?

Shandong Weigao Group Medical Polymer Co Ltd has achieved several significant milestones. The company expanded its product portfolio, developed innovative medical devices, and established a strong global presence. Shandong Weigao Group Medical Polymer Co Ltd successfully obtained various certifications and accreditations, affirming its commitment to quality and safety standards. The company also collaborated with renowned medical institutions and key industry players to advance healthcare solutions. Shandong Weigao Group Medical Polymer Co Ltd's consistent growth, dedication to customer satisfaction, and continuous research and development efforts have positioned it as a leading player in the medical polymer industry.

What is the history and background of the company Shandong Weigao Group Medical Polymer Co?

Shandong Weigao Group Medical Polymer Co Ltd is a renowned company in the medical industry. Established in 1988, it specializes in the production and distribution of medical devices and healthcare products. Over the years, Weigao Group has built a strong reputation for its commitment to technological advancements, quality manufacturing, and customer satisfaction. The company has expanded its presence globally, with a strong market share in China as well as a growing international presence. With a focus on research and development, Weigao Group continues to innovate and introduce new medical solutions, contributing to improved patient care worldwide.

Who are the main competitors of Shandong Weigao Group Medical Polymer Co in the market?

The main competitors of Shandong Weigao Group Medical Polymer Co Ltd in the market include Johnson & Johnson, Becton, Dickinson and Company, Medtronic plc, and Terumo Corporation.

In which industries is Shandong Weigao Group Medical Polymer Co primarily active?

Shandong Weigao Group Medical Polymer Co Ltd is primarily active in the medical and healthcare industry.

What is the business model of Shandong Weigao Group Medical Polymer Co?

The business model of Shandong Weigao Group Medical Polymer Co Ltd focuses on manufacturing and distributing medical devices and healthcare products. With a commitment to quality and innovation, the company specializes in the production of disposable medical consumables such as syringes, infusion sets, and catheters. Shandong Weigao Group Medical Polymer Co Ltd aims to provide effective and safe medical solutions to healthcare professionals and patients worldwide. As a leading player in the medical polymer industry, the company continuously invests in research and development, ensuring advancements in technology and maintaining a strong competitive edge in the market.

What is the P/E ratio of Shandong Weigao Group Medical Polymer Co 2024?

The Shandong Weigao Group Medical Polymer Co P/E ratio is 9.06.

What is the P/S ratio of Shandong Weigao Group Medical Polymer Co 2024?

The Shandong Weigao Group Medical Polymer Co P/S ratio is 1.4.

What is the Quality Investing of Shandong Weigao Group Medical Polymer Co?

The Quality Investing for Shandong Weigao Group Medical Polymer Co is 6/10.

What is the revenue of Shandong Weigao Group Medical Polymer Co 2024?

The expected Shandong Weigao Group Medical Polymer Co revenue is 14.07 B CNY.

How high is the profit of Shandong Weigao Group Medical Polymer Co 2024?

The expected Shandong Weigao Group Medical Polymer Co profit is 2.18 B CNY.

What is the business model of Shandong Weigao Group Medical Polymer Co

Shandong Weigao Group Medical Polymer Co Ltd is a leading company in the field of medical polymer products in China. The company operates in several areas, including medical technology, medical devices, medical consumables, and pharmaceutical packaging. The company offers a wide range of medical products, including cardiology products, wound care, surgical instruments and implants, anesthesia products, needles and syringes, as well as disposable products such as catheters and drainage systems. Products for blood transfusion, oncology, and infection control are also offered. Shandong Weigao Group Medical Polymer Co Ltd has an extensive customer base in China and also exports to international markets. The company places great emphasis on quality and adhering to industry standards. In the field of medical devices, the company offers products for patient diagnosis and monitoring, as well as rehabilitation and care. The company also manufactures products for operating rooms and intensive care units. Another important business area is pharmaceutical packaging. In recent years, the company has expanded its product range through acquisitions and investments in new technologies. It aims to provide high-quality products that meet both customer requirements and industry safety standards. The business model of Shandong Weigao Group Medical Polymer Co Ltd is based on innovation and quality. The company invests in research and development of new products and technologies. It has also built an extensive network of distribution partners and other companies in the industry to place its products in the market. The company also pursues a strategy of vertical integration. It owns several production facilities and maintains partnerships with various companies in the industry. This allows it to reduce costs and increase efficiency. Overall, Shandong Weigao Group Medical Polymer Co Ltd is a leading company in the field of medical polymer products in China. It has a wide product range and strives to offer high-quality products that meet customer requirements and industry safety standards.

What is the Shandong Weigao Group Medical Polymer Co dividend?

Shandong Weigao Group Medical Polymer Co pays a dividend of 0.17 CNY distributed over payouts per year.

How often does Shandong Weigao Group Medical Polymer Co pay dividends?

The dividend cannot currently be calculated for Shandong Weigao Group Medical Polymer Co or the company does not pay out a dividend.

What is the Shandong Weigao Group Medical Polymer Co ISIN?

The ISIN of Shandong Weigao Group Medical Polymer Co is CNE100000171.

What is the Shandong Weigao Group Medical Polymer Co WKN?

The WKN of Shandong Weigao Group Medical Polymer Co is A0M4WA.

What is the Shandong Weigao Group Medical Polymer Co ticker?

The ticker of Shandong Weigao Group Medical Polymer Co is 1066.HK.

How much dividend does Shandong Weigao Group Medical Polymer Co pay?

Over the past 12 months, Shandong Weigao Group Medical Polymer Co paid a dividend of 0.25 CNY . This corresponds to a dividend yield of about 5.64 %. For the coming 12 months, Shandong Weigao Group Medical Polymer Co is expected to pay a dividend of 0.27 CNY.

What is the dividend yield of Shandong Weigao Group Medical Polymer Co?

The current dividend yield of Shandong Weigao Group Medical Polymer Co is 5.64 %.

When does Shandong Weigao Group Medical Polymer Co pay dividends?

Shandong Weigao Group Medical Polymer Co pays a quarterly dividend. This is distributed in the months of July, July, November, November.

How secure is the dividend of Shandong Weigao Group Medical Polymer Co?

Shandong Weigao Group Medical Polymer Co paid dividends every year for the past 23 years.

What is the dividend of Shandong Weigao Group Medical Polymer Co?

For the upcoming 12 months, dividends amounting to 0.27 CNY are expected. This corresponds to a dividend yield of 5.7 %.

In which sector is Shandong Weigao Group Medical Polymer Co located?

Shandong Weigao Group Medical Polymer Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shandong Weigao Group Medical Polymer Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shandong Weigao Group Medical Polymer Co from 11/22/2024 amounting to 0.01 CNY, you needed to have the stock in your portfolio before the ex-date on 10/22/2024.

When did Shandong Weigao Group Medical Polymer Co pay the last dividend?

The last dividend was paid out on 11/22/2024.

What was the dividend of Shandong Weigao Group Medical Polymer Co in the year 2023?

In the year 2023, Shandong Weigao Group Medical Polymer Co distributed 0.172 CNY as dividends.

In which currency does Shandong Weigao Group Medical Polymer Co pay out the dividend?

The dividends of Shandong Weigao Group Medical Polymer Co are distributed in CNY.

All fundamentals about Shandong Weigao Group Medical Polymer Co

Our stock analysis for Shandong Weigao Group Medical Polymer Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shandong Weigao Group Medical Polymer Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.